251 related articles for article (PubMed ID: 31209793)
1. The potential markers of endocrine resistance among HR+ /HER2+ breast cancer patients.
Chen K; Quan J; Yang J; Chen Z
Clin Transl Oncol; 2020 Apr; 22(4):576-584. PubMed ID: 31209793
[TBL] [Abstract][Full Text] [Related]
2. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
3. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
4. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
5. Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.
Walter V; Fischer C; Deutsch TM; Ersing C; Nees J; Schütz F; Fremd C; Grischke EM; Sinn P; Brucker SY; Schneeweiss A; Hartkopf AD; Wallwiener M
Breast Cancer Res Treat; 2020 Aug; 183(1):137-144. PubMed ID: 32613540
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study.
Le Saux O; Lardy-Cleaud A; Frank S; Debled M; Cottu PH; Pistilli B; Vanlemmens L; Leheurteur M; Lévy C; Laborde L; Uwer L; D'hondt V; Berchery D; Lorgis V; Ferrero JM; Perrocheau G; Courtinard C; Mouret-Reynier MA; Velten M; Breton M; Parent D; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2019 Sep; 118():131-141. PubMed ID: 31330488
[TBL] [Abstract][Full Text] [Related]
7. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
Precht LM; Lowe KA; Atwood M; Beatty JD
Breast J; 2010; 16(4):362-8. PubMed ID: 20443786
[TBL] [Abstract][Full Text] [Related]
9. Effect of hormone therapy on long-term outcomes of patients with human epidermal growth factor receptor 2- and hormone receptor-positive metastatic breast cancer: real world experience in China.
Du F; Yuan P; Wang JY; Ma F; Fan Y; Luo Y; Xu BH
Asian Pac J Cancer Prev; 2015; 16(3):903-7. PubMed ID: 25735380
[TBL] [Abstract][Full Text] [Related]
10. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
12. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
Cristofanilli M; DeMichele A; Giorgetti C; Turner NC; Slamon DJ; Im SA; Masuda N; Verma S; Loi S; Colleoni M; Theall KP; Huang X; Liu Y; Bartlett CH
Eur J Cancer; 2018 Nov; 104():21-31. PubMed ID: 30308388
[TBL] [Abstract][Full Text] [Related]
13. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
[TBL] [Abstract][Full Text] [Related]
14. Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium.
Luyeye Mvila G; Batalansi D; Praet M; Marchal G; Laenen A; Christiaens MR; Brouckaert O; Ali-Risasi C; Neven P; Van Ongeval C
Breast; 2015 Oct; 24(5):642-8. PubMed ID: 26279132
[TBL] [Abstract][Full Text] [Related]
15. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
17. Incidence and Survival by Human Epidermal Growth Factor Receptor 2 Status in Young Women With Stage I-III Breast Cancer: SEER, 2010-2016.
Thomas A; Rhoads A; Suhl J; Conway KM; Hundley WG; McNally LR; Oleson J; Melin SA; Lynch CF; Romitti PA
Clin Breast Cancer; 2020 Aug; 20(4):e410-e422. PubMed ID: 32278642
[TBL] [Abstract][Full Text] [Related]
18. Survival in patients with HR+/HER2- metastatic breast cancer treated with initial endocrine therapy versus initial chemotherapy. A French population-based study.
Simon J; Chaix M; Billa O; Kamga AM; Roignot P; Ladoire S; Coutant C; Arveux P; Quantin C; Dabakuyo-Yonli TS
Br J Cancer; 2020 Sep; 123(7):1071-1077. PubMed ID: 32678278
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
20. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
